Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 157

1.

Ki67, E-cadherin, and p53 as prognostic indicators of long-term outcome after liver transplantation for metastatic neuroendocrine tumors.

Rosenau J, Bahr MJ, von Wasielewski R, Mengel M, Schmidt HH, Nashan B, Lang H, Klempnauer J, Manns MP, Boeker KH.

Transplantation. 2002 Feb 15;73(3):386-94.

PMID:
11884935
[PubMed - indexed for MEDLINE]
2.

Total hepatectomy and liver transplantation for metastatic neuroendocrine tumors of the pancreas - a single center experience with ten patients.

Lang H, Schlitt HJ, Schmidt H, Flemming P, Nashan B, Scheumann GF, Oldhafer KJ, Manns MP, Raab R.

Langenbecks Arch Surg. 1999 Aug;384(4):370-7. Review.

PMID:
10473858
[PubMed - indexed for MEDLINE]
3.

Clinical relevance of transforming growth factor alpha, epidermal growth factor receptor, p53, and Ki67 in colorectal liver metastases and corresponding primary tumors.

De Jong KP, Stellema R, Karrenbeld A, Koudstaal J, Gouw AS, Sluiter WJ, Peeters PM, Slooff MJ, De Vries EG.

Hepatology. 1998 Oct;28(4):971-9.

PMID:
9755233
[PubMed - indexed for MEDLINE]
4.

Liver transplantation for metastatic neuroendocrine tumors.

Lang H, Oldhafer KJ, Weimann A, Schlitt HJ, Scheumann GF, Flemming P, Ringe B, Pichlmayr R.

Ann Surg. 1997 Apr;225(4):347-54. Review.

PMID:
9114792
[PubMed - indexed for MEDLINE]
Free PMC Article
5.

Endocrine tumours of the gastrointestinal tract. Transplantation in the management of metastatic endocrine tumours.

Pascher A, Klupp J, Neuhaus P.

Best Pract Res Clin Gastroenterol. 2005 Aug;19(4):637-48.

PMID:
16183532
[PubMed - indexed for MEDLINE]
6.

Tissue microarray analysis of the prognostic value of E-cadherin, Ki67, p53, p27, survivin and MSH2 expression in upper urinary tract transitional cell carcinoma.

Fromont G, Rouprêt M, Amira N, Sibony M, Vallancien G, Validire P, Cussenot O.

Eur Urol. 2005 Nov;48(5):764-70. Epub 2005 Aug 1.

PMID:
16126329
[PubMed - indexed for MEDLINE]
7.

Liver transplantation for gastroenteropancreatic neuroendocrine cancers: Defining selection criteria to improve survival.

van Vilsteren FG, Baskin-Bey ES, Nagorney DM, Sanderson SO, Kremers WK, Rosen CB, Gores GJ, Hobday TJ.

Liver Transpl. 2006 Mar;12(3):448-56.

PMID:
16498656
[PubMed - indexed for MEDLINE]
Free Article
8.
9.

Orthotopic liver or multivisceral transplantation as treatment of metastatic neuroendocrine tumors.

Olausson M, Friman S, Herlenius G, Cahlin C, Nilsson O, Jansson S, Wängberg B, Ahlman H.

Liver Transpl. 2007 Mar;13(3):327-33.

PMID:
17318853
[PubMed - indexed for MEDLINE]
Free Article
10.

[Prognostic significance of Ki67 and p53 protein in small bowel stromal tumor immunopositive for CD117].

Liu P, Na J, Zhang J, Zhang Y.

Beijing Da Xue Xue Bao. 2003 Feb 18;35(1):28-32. Chinese.

PMID:
12920804
[PubMed - indexed for MEDLINE]
Free Article
11.

Tissue microarray analysis of cytoskeletal actin-associated biomarkers gelsolin and E-cadherin in urothelial carcinoma.

Rao J, Seligson D, Visapaa H, Horvath S, Eeva M, Michel K, Pantuck A, Belldegrun A, Palotie A.

Cancer. 2002 Sep 15;95(6):1247-57.

PMID:
12216092
[PubMed - indexed for MEDLINE]
Free Article
12.

Hepatic surgery for metastases from neuroendocrine tumors.

Sarmiento JM, Que FG.

Surg Oncol Clin N Am. 2003 Jan;12(1):231-42. Review.

PMID:
12735141
[PubMed - indexed for MEDLINE]
13.

Treatment of liver metastases in patients with neuroendocrine tumors.

Frilling A, Rogiers X, Malagó M, Liedke OM, Kaun M, Broelsch CE.

Langenbecks Arch Surg. 1998 Mar;383(1):62-70.

PMID:
9627173
[PubMed - indexed for MEDLINE]
14.

[Is liver transplantation as surgical therapy concept in metastases of neuroendocrine tumors justified?].

Lang H, Oldhafer KJ, Schlitt HJ, Scheumann GF, Ringe B, Pichlmayr R.

Langenbecks Arch Chir Suppl Kongressbd. 1996;113:416-8. German.

PMID:
9101890
[PubMed - indexed for MEDLINE]
15.

Liver transplantation for treatment of metastatic neuroendocrine tumors.

Ahlman H, Friman S, Cahlin C, Nilsson O, Jansson S, Wängberg B, Olausson M.

Ann N Y Acad Sci. 2004 Apr;1014:265-9.

PMID:
15153443
[PubMed - indexed for MEDLINE]
16.

Biological markers and DNA flow cytometric analysis in radically resected patients with non-small cell lung cancer. A study of the Perugia Multidisciplinary Team for Thoracic Tumors.

Ludovini V, Pistola L, Gregorc V, Floriani I, Rulli E, Di Carlo L, Semeraro A, Daddi G, Darwish S, Stocchi L, Tofanetti FR, Bellezza G, Sidoni A, Tognellini R, Crinò L, Tonato M.

Tumori. 2008 May-Jun;94(3):398-405.

PMID:
18705409
[PubMed - indexed for MEDLINE]
17.

Loss of nuclear p27 expression and its prognostic role in relation to cyclin E and p53 mutation in gastroenteropancreatic neuroendocrine tumors.

Grabowski P, Schrader J, Wagner J, Hörsch D, Arnold R, Arnold CN, Georgieva I, Stein H, Zeitz M, Daniel PT, Sturm I.

Clin Cancer Res. 2008 Nov 15;14(22):7378-84. doi: 10.1158/1078-0432.CCR-08-0698.

PMID:
19010853
[PubMed - indexed for MEDLINE]
Free Article
18.

Proliferation of antigen MIB-1 in metastatic carcinoid tumours removed at liver transplantation: relevance to prognosis.

Amarapurkar AD, Davies A, Ramage JK, Stangou AJ, Wight DG, Portmann BC.

Eur J Gastroenterol Hepatol. 2003 Feb;15(2):139-43.

PMID:
12560757
[PubMed - indexed for MEDLINE]
19.

Primary and secondary hepatic manifestation of neuroendocrine tumors.

Pascher A, Steinmüller T, Radke C, Hosten N, Wiedenmann B, Neuhaus P, Bechstein WO.

Langenbecks Arch Surg. 2000 Jul;385(4):265-70.

PMID:
10958510
[PubMed - indexed for MEDLINE]
20.

Predictive factors associated with long-term survival in patients with neuroendocrine tumors of the pancreas.

Chu QD, Hill HC, Douglass HO Jr, Driscoll D, Smith JL, Nava HR, Gibbs JF.

Ann Surg Oncol. 2002 Nov;9(9):855-62.

PMID:
12417506
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk